Traxens Announces Partnership With COSCO
Traxens, a company that provides high-value data and services for the supply chain industry, announces today a major partnership with COSCO Shipping Logistics that aims to promote a full set of IoT data services based on Traxens cutting-edge smart container solutions. Both companies are carrying out a test program to provide IoT data services to COSCO Shipping Logistics’ large worldwide base of beneficial cargo owners (BCO) customers and aiming to join force in promoting supply chain digitalization. This follows the opening of Traxens’ China office – its first outside of France.
COSCO is a leading global shipping company and a container logistics operator in China. In partnering with COSCO, Traxens will be able to demonstrate its capacity in creating customer values through promoting its smart container solutions and digital services, and significantly contributing to the ongoing digitalization of the global container logistics industry. As the global supply chain becomes more and more competitive, improved tracking and smart data management is an increasingly important differentiation factor for all the major players in the shipping industry.
Through this partnership, COSCO will be able to offer premium data services to its large base of BCOs who are seeking door-to-door visibility and ever-increasing efficiency in their supply chains. This joint development in container supply chain digitalization marks a milestone in Traxens’ international expansion strategy and will help the company push forward with further business development in Asia.
“Our main focus as a business is to be able to create substantial customer value by delivering superior solution and services through technological innovation and global customer support capacity” said David Marchand, Traxens CEO. “Our partnership with COSCO will greatly benefit cargo owners and end-users and encourage further digitalization of the container logistics industry to the benefit of customers worldwide.”
“Traxens is delighted to be working with COSCO, providing its industry-proven smart container solutions to help streamline the company’s operations and enhance customers experience,” said Vincent Gu, managing director, Traxens Asia-Pacific. “Providing fleets with global visibility, exception management and business intelligence is what Traxens does best. By partnering up with global shipping companies such as COSCO we are able to demonstrate what our market-leading IoT solutions are capable of, giving client companies end-to-end shipment visibility and predictive insights that will benefit the end-users and the whole industry.”
“Through our partnership with Traxens, we aim to be at the forefront of digitalization and to maintain our leadership in the global container logistics industry ” said Sheng Liu, general manager of the container logistics division of COSCO SHIPPING Logistics. “As a leading global logistics company, we always pay close attention to the needs of our customers in their supply chain. We believe that the IoT services developed by Traxens are important to improve tracking and management of moving assets.”
About COSCO Shipping
COSCO SHIPPING Logistics Co., Ltd (COSCO SHIPPING Logistics), affiliated to CHINA COSCO SHIPPING CORPORATION LIMITED, is an international integrated logistics enterprise with shipping logistics as its core. It can provide modernized and professional whole-process logistics and supply chain solutions for customers at home and abroad. With a strong reputation and professional service capabilities, it is an important partner for governments, ports, railways, airports and large multinational companies.
The company, with headquarters in Beijing, is merged with CHINA COSCO Logistics Co., Ltd.(a part of COSCO Group), China Shipping Logistics Co., Ltd. (China Shipping Group) and China Shipping Agency Co., Ltd. (China Shipping Group). It was launched on December 21, 2016. China Ocean Shipping Tally Company was incorporated into COSCO SHIPPING Logistics after integration on September 18, 2017.
The company’s service network covers 30 provinces in China and many other countries and regions in Europe, America, Asia and Africa. There are over 600 sales and service points throughout the world; such broad sales and service networks provide customers with a full range of logistics solutions. Since its establishment, COSCO Shipping Logistics has won the Golden Pegasus Prize and has for many years been recognised as one of the National Advanced Logistics Enterprises.
http://www.cosco-logistics.com.cn/
About Traxens
Traxens drives digital transformation in the global supply chain. The company’s breakthrough IoT technology, data science expertise, global logistics experience and standards leadership unlock the value of real-time data generated from cargo assets shipped by sea, rail and road. Traxens is trusted by hundreds of global cargo owners, enabling them to reduce door-to-door transport costs, optimize their investments and minimize risk. By partnering with the world’s leading shipping lines, rail carriers and smart ports, Traxens helps all members of the global supply chain ecosystem improve decision making, operations and customer service. Traxens is privately held and headquartered in Marseille, France.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005361/en/
Contact information
Géraldine Saunière
Director of Communications
Mail: g.sauniere@traxens.com
Tel: +33-695-915-899
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom